[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
August 2006

Pimecrolimus Cream, 1%, vs Hydrocortisone Acetate Cream, 1%, in the Treatment of Facial Seborrheic Dermatitis: A Randomized, Investigator-Blind, Clinical Trial

Arch Dermatol. 2006;142(8):1065-1086. doi:10.1001/archderm.142.8.1066

Seborrheic dermatitis is a chronic relapsing skin disorder that presents with erythema, scaling, and pruritus. It is estimated that between 3% and 5% of the population worldwide are affected by seborrheic dermatitis.1 Recent studies have shown the efficacy of pimecrolimus in treating facial seborrheic dermatitis.25 The purpose of this study was to compare the safety and efficacy of topical pimecrolimus with hydrocortisone acetate in the treatment of patients with facial seborrheic dermatitis.

×